

釈迦堂敏、早田哲郎、向坂彰太郎、C型肝炎に対するインターフェロン療法における治療効果に影響する因子の検討-当院において10年間経験した331例の成績から-、福岡大医紀，2011，38(1)，17-25

(3) Satoshi Shakado, Yuko Akehi, Kaoru Yotsumoto, Atsushi Fukunaga, Shizuka Kuno, Takashi Tanaka, Kunitoshi Sakurai, Hideyuki Iwashita, Shuichi Ueda, Genryu Hirano, Keiji Yokoyama, Daisuke Morihara, Shinya Nishizawa, Masaharu Sakamoto, Akira Anan, Yasuaki Takeyama, Makoto Irie, Kaoru Iwata, Tetsuro Sohda, Shotaro Sakisaka, A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin, *Clinical Journal of Gastroenterology*, 2011, 4, 255-261

(4) 釈迦堂敏、西澤新也、福永篤志、四本かおる、久能志津香、櫻井邦俊、岩下英之、平野玄竜、上田秀一、横山圭二、森原大輔、坂本雅晴、阿南 章、竹山康章、入江 真、岩田 郁、早田哲郎、向坂彰太郎、福岡大学消化器内科における10年間の急性肝障害患者の臨床的検討(2000-2009)、福岡大医紀，2011，38(1)，53-58

2. 学会発表

1) 田中崇、高田和英、吉兼誠、渡邊洋、向坂彰太郎: B型慢性肝炎に対するエンテカビル
の長期治療成績 第39回日本肝臓学会西部
会 岡山 2011.12

2) 渡邊洋、田中崇、吉兼誠、向坂彰太郎:
Serotype1 かつ高ウイルス量の C 型慢性肝炎
症例に対する PEG-IFN+RBV 治療の治療効
果を規定する因子-特に IL28B 遺伝子多型と

HCV-Core70 変異-の解析 第 39 回日本肝
臓学会西部会 岡山 2011.12

3) 渡邊洋、田中崇、吉兼誠、向坂彰太郎: C
型慢性肝炎症例に対するペグインターフェロ
ン+リバビリン48週間治療効果規定因子とし
ての IL28B 遺伝子多型と HCV-Core70 変異
の解析 第 98 回日本消化器病学会九州支部
例会 長崎 2011.11

4) 森原大輔、西澤新也、釈迦堂敏、國本英
雄、久能志津香、福永篤志、四本かおる、平
野玄竜、岩下英之、櫻井邦俊、上田秀一、横
山圭二、坂本雅晴、阿南章、竹山康章、入江
真、岩田 郁、早田哲郎、向坂彰太郎: IL28B
遺伝子多型と γ GTP の組み合わせは
Null-virological response の最も有用な予測因
子である 第 15 回日本肝臓学会大会 福岡
2011.10

5) 釈迦堂敏、森原大輔、西澤新也、四本か
おる、久能志津香、福永篤志、櫻井邦俊、岩
下英之、平野玄竜、横山圭二、上田秀一、坂
本雅晴、阿南章、竹山康章、入江真、岩田郁、
早田哲郎、向坂彰太郎: C 型慢性肝炎に対す
るペグインターフェロン、リバビリン治療効果に
かかわる宿主側・ウイルス側因子の検討 第
97 回日本消化器病学会九州支部例会 福岡
2011.6

6) 坂本雅晴、釈迦堂敏、森原大輔、福永篤
志、久能志津香、櫻井邦俊、上田秀一、岩下
英之、平野玄竜、横山圭二、阿南 章、竹山
康章、入江 真、岩田 郁、早田哲郎、向坂彰
太郎: C 型肝硬変に対するインターフェロン治
療後の AFP 値は肝発癌の予測因子となる 第
47 回日本肝臓学会総会 東京 2011.6

7) 渡邊洋、向坂彰太郎: C 型慢性肝炎に対
するペグインターフェロン+リナビリン 48 週間治

療のSVRを規定する因子、特にIL28B遺伝子の解析 第47回日本肝臓学会総会 東京
2011.6

H. 知的財産権の出願・登録状況（予定を含む。）

1. 特許取得 なし
2. 実用新案登録 なし

研究実施者

西澤新也 福岡大学医学部消化器内科

IV. 研究成果の刊行に関する一覧表

IV. 研究成果の刊行に関する一覧表

書 籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
芥田憲夫 熊田博光	肝疾患治療薬	高久史麿	治療薬ハンドブック	じほう	東京	2011	524-529
熊田博光	B型慢性肝炎に対する治療	熊田博光	B型慢性肝炎のマネジメント	医薬ジャーナル社	大阪	2011	1-105
芥田憲夫 熊田博光	C型慢性肝炎の治療効果予測因子	井廻道夫	これでわかる慢性肝炎の治療戦略	羊土社	東京	2011	79-87
荒瀬康司 熊田博光	C型慢性肝炎に対する新しい治療法	菅野健太郎 上西紀夫 井廻道夫	消化器疾患最新の治療2011-2012	南江堂	東京	2011	25-28
熊田博光	これだけは知っておきたいB型慢性肝炎の診断と治療	熊田博光	これだけは知っておきたいB型慢性肝炎の診断と治療	医薬ジャーナル社	大阪	2011	1-107
岡上 武、 南 祐仁	B型慢性肝炎に対する治療学の進歩と展望		新時代のウイルス性肝炎	株式会社 日本臨床社	東京	2011	469-474
岡上 武	NAFLD	菅野健太郎、 上西紀夫、 井廻道夫	消化器疾患最新の治療2011-2012	南江堂	東京	2011	316-318
狩野吉康、 豊田成司	C型慢性肝炎 PEG-IFN/RBV 併用療法の再燃・無効例をいかに治療するか	嶋田達哉	消化器Book	羊土社	東京	2011	98-105
桶谷 眞、 坪内博仁	抗悪性腫瘍薬、免疫抑制薬によるHBV再活性化とその対応		日本臨床 新時代のウイルス性肝炎学:基礎・臨床研究の進歩	日本臨床社	大阪	2011	520-525
泉 並木	ウイルスおよび宿主因子に基づいたC型肝炎の治療	森正樹、 下瀬川徹、 金子周一、 松本俊治、 寺田弘司	消化器疾患の最新医療	先端医療技術研究所	東京	2011	104-107
泉 並木	健康診断で肝臓の数値が気になるとき読む本	泉 並木	健康診断で肝臓の数値が気になるとき読む本	幻冬舎	東京	2011	全部
泉 並木	肝癌の治療	林紀夫、 日比紀文、 上西紀夫、 下瀬川徹	Annual Review 消化器2012	中外医学社	東京	2012	174-184
泉 並木	ウイルス肝炎の治療戦略 序文	工藤正俊、 泉 並木	ウイルス肝炎の治療戦略	診断と治療社	東京	2010	vii

雑 誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Kamatani N, Nakamura Y, Chayama K, <u>Kumada H.</u>	Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.	Hepatology	53(2)	415-21	2011
C Nelson H, Kobayashi M, Akuta N, Suzuki F, <u>Kumada H.</u> , Abe H, Miki D, Imamura M, Ochi H, Katanamik N, Nakamura Y, Chayama K.	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut	60	261-7	2011
Kawaoka T, C Nelson H, Ohishi W, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Tsunoda T, Nakamura Y, <u>Kumada H.</u> , Chayama K.	Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.	J Hepatol	54	408-14	2011
Chayama K, C Nelson H, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, <u>Kumada H.</u>	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.	J Infect Dis	204	84-93	2011
Miki D, Ochi H, C Nelson H, Abe H, Yashima T, Aikata H, Ikeda K, <u>Kumada H.</u> , Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura Y, Kamatani N, Chayama K.	Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.	Nat Genet	43(8)	797-800	2011
Arase Y, Suzuki Y, Suzuki F, Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.	Internal Medicine	50	2083-2088	2011
Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, <u>Kumada H.</u>	Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.	Hepatol Res.	41 (11)	1036-45	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arase Y, Suzuki F, Kawamura Y, Suzuki Y, Kobayashi M, Matsumoto N, Akuta N, Sezaki H, Hosaka T, Ogawa K, Imai N, Seko Y, Saito S, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.	Hepatol Res.	41 (10)	946-54	2011
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H.</u>	Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.	Oncology	80 (3-4)	188-94	2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H.</u>	Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.	J Med Virol	83(6)	1016-22	2011
Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H.</u>	Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.	Liver Int.	31(5)	692-9	2011
Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Imai N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, <u>Kumada H.</u> , Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kobayashi T.	Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.	Hepatol Res.	41(6)	524-9	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kawamura Y, Ikeda K, Seko Y, Hosaka T, Kobayashi M, Saitoh S, <u>Kumada H.</u>	Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation.	AJR	197 (4)	W665-73	2011
<u>Watanabe S</u> , Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, <u>Kumada H</u> , Imawari M; PERFECT Study Group.	Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res.	41 (10)	955-964	2011
Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, <u>Kumada H</u> , Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K.	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.	Eur J Cancer	47 (14)	2117-27	2011
Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, <u>Kumada H</u> , Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T.	The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.	Intern Med.	50 (10)	1081-7	2011
Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, <u>Kumada H</u> , Toyota J.	Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.	J Gastroenterol	46(7)	929-37	2011
Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, <u>Kumada H</u> , Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.	J Med Virol	83(6)	1048-57	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, <u>Kumada H.</u>	Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.	J Gastroenterol	46(4)	545-55	2011
Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, <u>Kumada H</u> , Nakamura Y, Hayes CN, Chayama K.	IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.	J Gen Virol	92 (Pt 5)	1071-81	2011
Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, <u>Kumada H.</u>	Efficacy and safety to telaprevir, a new protease inhibitor, for difficult to treat patients with genotype 1 chronic hepatitis C.	J Viral Hepatol	Epub ahead of print	134-142	2012
Yamada I, Suzuki F, Kamiya N, Aoki K, Sakurai Y, Kanou M, Matsui H, <u>Kumada H.</u>	Safety, pharmacokinetics, and resistant variants of telaprevir for 12 weeks in hepatitis C virus genotype 1b infection.	J Viral Hepatol	Epub ahead of print	112-119	2012
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, <u>Kumada H.</u>	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.	Intervirology	Epub ahead of print		2011
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, <u>Kumada H.</u>	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.	Intervirology	Epub ahead of print		2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Kumada H</u> , Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N.	Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.	J Hepatol	Epub ahead of print	78-84	2011
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, <u>Kumada H</u> .	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma.	Am J Gastroenterol	Epub ahead of print		2011
Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, <u>Kumada H</u> .	Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders.	Hepatology	Epub ahead of print		2011
鈴木義之、瀬崎ひとみ、芥田憲夫、鈴木文孝、今井則博、平川美晴、川村祐介、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、小林万利子、 <u>熊田博光</u>	NS5A阻害剤とNS3プロテアーゼ阻害剤併用投与における早期抗ウイルス効果	肝臓	52(2)	147-9	2011
保坂哲也、鈴木文孝、小林正宏、瀬古裕也、今井則博、平川美晴、川村祐介、瀬崎ひとみ、芥田憲夫、鈴木義之、斎藤聡、荒瀬康司、池田健次、小林万利子、 <u>熊田博光</u>	B型慢性肝疾患に対する核酸アナログ療法によるHBs抗原消失とその関連因子の検討	肝臓	52(4)	255-7	2011
小林万利子、鈴木文孝、鈴木義之、芥田憲夫、瀬崎ひとみ、川村祐介、瀬古裕也、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、 <u>熊田博光</u>	コバスTaqManHBV「オート」v2.0における同一時の血清検体と血漿検体のHBVDNA検出率の検討	肝臓	52(11)	756-7	2011
<u>Okanoue T</u> , Umemura A, Yasui K, Itoh Y	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan	J Gastroenterol Hepatol	26 (Suppl)	153-162	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Chayama K, Hayes CN, Yoshioka K, Moriwaki H, <u>Okanoue T</u> , Sakisaka S, Takehara T, Oketani M, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike H, Ueno Y, Yotsuyanagi H, Kumada H	Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C	J Gastroenterol	46	545-555	2011
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, <u>Okanoue T</u>	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma	Clin Gastroenterol Hepatol	9	428-433	2011
Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo T, Fujii H, Minami M, Yasui K, Mitsuyoshi H, <u>Okanoue T</u> , Takehara T, Hisa Y, Onji M, Yoshikawa T	Simple formula to predict response to peginterferon alfa 2b and ribavirin therapy in genotype 1 chronic hepatitis C patients with high viral loads	Hepatol Res	41	126-132	2011
Itoh Y, Nishimura T, Yamaguchi K, Yokomizo C, Fujii H, Minami M, Nagao Y, Sumida Y, Hashimoto H, Umemura A, Shima T, <u>Okanoue T</u> , Yoshikawa T	Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy	Hepatol Res	41	1145-1152	2011
Yokomizo C, Yamaguchi K, Itoh Y, Nishimura T, Umemura A, Minami M, Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, <u>Okanoue T</u> , Yoshikawa T	High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells	Cancer Lett	310	140-147	2011
Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, Kumada H, <u>Toyota J</u>	Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.	J Gastroenterol	46	929-937	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
小関 至、狩野吉康、 <u>豊田成司</u> 、高橋祥一、川上由育、茶山一彰、芥田憲夫、鈴木文孝、熊田博光	PEG-IFN/Ribavirin/Telaprevir 三剤併用療法における薬剤投与率の抗ウイルス効果に及ぼす影響	肝臓		69-77	2012
Asahina Y, <u>Izumi N</u> et al.	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.	Hepatol	55	20-9	2012
Kurosaki M, <u>Izumi N</u> , et al.	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	In press		2012
Kurosaki M, <u>Izumi N</u> , et al.	Relationship between polymorphisms of the inosine triphosphate gene and anemia or outcome after treatment with pegylated interferon and ribavirin.	Antivir Ther	16	685-94	2011
Itakura J, <u>Izumi N</u> et al.	Changes days can predict the undetectable time in hepatitis C viral load during first 14 point of serum viral load by pegylated interferon and ribavirin therapy.	Hepatol Res	41	217-24	2011
Watanabe S, <u>Izumi N</u> et al.	Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res	41	955-64	2011
Shindo H, Enomoto N, <u>Izumi N</u> et al.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients	Hepatol Int	In press		2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kurosaki M, <u>Izumi N</u> , et al.	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.	J Med Virol	83	445-52	2011
<u>Izumi N</u> , Asahina Y et al.	Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.	Hepat Res Treat	2010	703602	2010
Kurosaki M, <u>Izumi N</u> , et al.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54	439-48	2011
Tsuchiya K, <u>Izumi N</u> et al.	Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.	Oncology	80	278-88	2011
Kuzuya T, <u>Izumi N</u> et al.	Early decrease in α -fetoprotein but not des- γ -carboxy prothrombin predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.	Oncology	81	251-8	2011
Kawaguchi T, <u>Izumi N</u> et al.	Branched-chain amino acids as pharmacological nutrients in chronic liver disease.	Hepatology	54	1063-70	2011
<u>Izumi N</u>	Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.	Hepatol Res	In press		2012
<u>Izumi N</u>	Recent advances of radiofrequency ablation for early hepatocellular carcinoma	J Gastroenterol Hepatol	26	115-22	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsumoto A, <u>Tanaka E</u> , Morita S, Yoshizawa K, Umemura T, Joshita S.	Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection.	J Gastroenterol	In press		2012
Matsumoto A, <u>Tanaka E</u> , Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsushashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.	Hepatol Res	42	139-149	2012
<u>Tanaka E</u> , Urata Y.	Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-alpha inhibitors.	Hepatol Res			2011
Ichikawa-Yamada Y, Joshita S, Tsukahara Y, Kimura T, Morita S, Kamijo A, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, <u>Tanaka E</u> .	Early detection of interstitial pneumonia by monitoring KL-6 in a chronic hepatitis C patient undergoing pegylated interferon and ribavirin therapy.	Hepatol Res	41(9)	904-909	2011
Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsushashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, <u>Tanaka E</u> , Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.	Hum Mol Genet	20 (17)	3507-3516	2011
Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, <u>Tanaka E</u>	Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C.	Antivir Ther	16(7)	1073-1080	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, <u>Tanaka E</u>	Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.	Hepatol Res	41(6)	587-593	2011
Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, <u>Tanaka E</u> , Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M.	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.	J Med Virol	83(5)	871-878	2011
Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, <u>Tanaka E</u>	Association of Serum Cytokine Levels with Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C Patients.	J Infect Dis	203(8)	1087-1095	2011
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, <u>Tanaka E</u> , Kumada H, Izumi N, Mizokami M, Kudo M	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009	Hepatol Res	41(1)	1-21	2011
秋澤忠男, 平方秀樹, 友雅司, 秋葉隆, 洞和彦, 井廻道夫, 佐藤千史, <u>田中榮司</u> , 泉並木, 原田孝司, 安藤亮一, 菊地勘, 透析患者のC型ウイルス肝炎治療ガイドライン作成ワーキンググループ	社団法人日本透析医学会「透析患者のC型ウイルス肝炎治療ガイドライン」	日本透析医学会雑誌	44(6)	481-531	2011
<u>田中榮司</u>	透析患者におけるB型肝炎ウイルスマーカー測定の意味	日本透析医学会雑誌	26(1)	55-61	2011
Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, <u>Chayama K</u> , Alrefai WA, Uprichard SL.	Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.	Nat Med	18(2)	281-5	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, <u>Chayama K</u>	Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus.	Hepatology	54(3)	764-71	2011
Hiraga N, Imamura M, Abe H, Nelson Hayes C, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, <u>Chayama K</u> .	Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo.	Hepatology	54(3)	781-88	2011
Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, Abe H, Miki D, Imamura M, Takahashi S, Ochi_H, Hayes CN, Miya F, Tsunoda T, <u>Chayama K</u>	Hepatitis C virus response in the liver of the hyman hepacyte chimeric mouse.	PLoS One.	6	e23856.	2011
Tsuge M, Takahashi S, Hiraga N, Fujimoto Y, Zhang Y, Mitsui F, Abe H, Kawaoka T, Imamura M, Ochi H, Hayes CN, <u>Chayama K</u> .	Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice.	J Infect Dis	2	224-8	2011
Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, <u>Chayama K</u> , Choi Y, Krawczynski K, Liang TJ, Wakita T, Kato T.	In Vivo adaptation of hepatitis C virus for efficient virus production and evasion of apoptosis.	Hepatology	54(2)	425-33	2011
Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, <u>Chayama K</u>	Elimination of Hepatitis C Virus by Short Term NS3-4A and NS5B Inhibitor Combination Therapy in Human Hepatocyte Chimeric Mice.	J Hepatol	54(5)	872-8	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, <u>Chayama K</u>	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.	J Hepatol	55(1)	11-8	2011
松本照雄、早田哲郎、西澤新也、森原大輔、田中 崇、上田秀一、阿南 章、竹山康章、入江 真、岩田 郁、 <u>釈迦堂敏、向坂彰太郎</u>	慢性肝疾患における肝線維化の非侵襲的評価 -FibroScanの使用経験から-	福岡大医紀	38(1)	1-6	2011
森原大輔、西澤新也、福永篤志、四本かおる、久能志津香、櫻井邦俊、平野玄竜、岩下英之、上田秀一、横山圭二、坂本雅晴、阿南 章、竹山康章、入江 真、岩田 郁、 <u>釈迦堂敏、早田哲郎、向坂彰太郎</u>	C型肝炎に対するインターフェロン療法における治療効果に影響する因子の検討-当院において10年間経験した331例の成績から-	福岡大医紀	38(1)	17-25	2011
Satoshi Shakado, Yuko Akehi, Kaoru Yotsumoto, Atsushi Fukunaga, Shizuka Kuno, Takashi Tanaka, Kunitoshi Sakurai, Hideyuki Iwashita, Shuichi Ueda, Genryu Hirano, Keiji Yokoyama, Daisuke Morihara, Shinya Nishizawa, Masaharu Sakamoto, Akira Anan, Yasuaki Takeyama, Makoto Irie, Kaoru Iwata, Tetsuro Sohda, <u>Shotaro Sakisaka</u>	A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin	Clinical Journal of Gastroenterology	4	255-261	2011
釈迦堂敏、西澤新也、福永篤志、四本かおる、久能志津香、櫻井邦俊、岩下英之、平野玄竜、上田秀一、横山圭二、森原大輔、坂本雅晴、阿南 章、竹山康章、入江 真、岩田 郁、早田哲郎、 <u>向坂彰太郎</u>	福岡大学消化器内科における10年間の急性肝障害患者の臨床的検討(2000-2009)	福岡大医紀	38(1)	53-58	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hikita H, <u>Takehara T</u> , Kodama T, Shimizu S, Shigekawa M, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Shimizu S, Tsujimoto Y, Hayashi N.	Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice.	Hepatology	54(1)	240-51.	2011
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, <u>Takehara T</u> , Hayashi N.	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol.	54(4)	604-11.	2011
Miyagi T, Shimizu S, Tatsumi T, Nishio K, Hiramatsu N, Kanto T, Hayashi N, <u>Takehara T</u> .	Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.	J Gastroenterol.	46(8)	1020-30.	2011
Tsunematsu H, Tatsumi T, Kohga K, Yamamoto M, Aketa H, Miyagi T, Hosui A, Hiramatsu N, Kanto T, Hayashi N, <u>Takehara T</u> .	Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells.	Int J Cancer.	130 (2)	356-64.	2011
Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari S, Saishoji A, Kure T, Ohno K, Toyokura E, Imanaka D, Moriuchi A, Uto H, <u>Oketani M</u> , Hashiguchi T, Tsubouchi H.	Highly sensitive lens culinaris agglutinin-reactive α -fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease.	Oncol Rep.	26(5)	1227-33	2011
<u>Oketani M</u> , Ido A, Tsubouchi H.	Changing etiologies and outcomes of acute liver failure: A perspective from Japan.	J Gastroenterol Hepatol.	26 Suppl 1	65-71	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki Y, <u>Yotsuyanagi H</u> , Yasuda K, Okuse C, Moriya K, Suzuki M, Kato T, Iino S, Koike K, Itoh F.	Nucleic acid substitutions and response to interferon in HBeAg-positive chronic hepatitis B patients with genotype C HBV infection.	J St. Marianna Univ.	2	31-38	2011
<u>Nomura H</u> , Miyagi Y, Tanimoto H, Yamashita N, Oohashi S, Nishiura S.	Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin	Hepatol Res.	42		2012
Kainuma M, Furusyo N, Azuma K, Kajiwara E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Shimoda S, Hayashi J	Pegylated interferon α -2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.	Hepatol Res.	42	33-41	2012
Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, <u>Nomura H</u> , Hige S, Adachi H, Hino K, Yatsushashi H, Orito E, Kani S, Tanaka Y, Mizokami M.	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.	J Clin Microbiol.	49	1853-1860	2011
Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, <u>Nomura H</u> , Seike M, Ueno Y, Yotsuyanagi H, Kumada H.	Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.	J Gastroenterol.	46	545-555	2011
Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, <u>Nomura H</u> , Sugauchi F, Nojiri S, Joh T, Mizokami M.	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial	Hepatol Res.	41	505-511	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>野村秀幸</u>	C型肝炎の高ウイルス療法 の実際	Medical Practice	28	1435-1439	2011
<u>野村秀幸</u>	C型急性肝炎の動向と診断 ・治療	日本臨床	69	161-164	2011
<u>野村秀幸</u>	新しいプロテアーゼ阻害剤 : MK7009	肝胆膵	63	1219-1223	2011
Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.	J Med Virol.	84(3)	438-44	2012
<u>Yoshioka K</u> , Hashimoto S	Can non-invasive assessment of liver fibrosis replace liver biopsy?	Hepatol Res	(in press)		2011
Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, <u>Yoshioka K</u>	Reduction of liver stiffness by antiviral therapy in chronic hepatitis B	J Gastroenterol	46 (11)	1324-34	2011
Chayama K, Hayes CN, <u>Yoshioka K</u> , Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H	Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C	J Gastroenterol	46(4) :	545-555	2011
Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H	Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.	J Viral Hepat	18(4)	280-286	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H.	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy	Liver Int	31(9)	1359-65.	2011
Harata M, Hashimoto S, Kawabe N, Nitta Y, Murao M, Nakano T, Arima Y, Shimazaki H, Ishikawa T, Okumura A, Ichino N, Osakabe K, Nishikawa T, <u>Yoshioka K</u> .	Liver stiffness in extrahepatic cholestasis correlates positively with bilirubin and negatively with alanine aminotransferase	Hepatol Res	41(5)	423-429	2011
Honda K, <u>Seike M</u> , Maehara S, Tahara K, Anai H, Moriuchi A and Muro T	Lamivudine treatment enabling right hepatectomy for HCC in decompensated cirrhosis	World J Gastroenterol	in press.		2012
上尾哲他、石田哲也、永松秀康、成田竜一、高橋健、小寺隆元、向井亮、米増博俊、福地聡士、 <u>清家正隆</u>	EUS 所見より術前診断し、内視鏡的に切除し得た胃 Hamartomatous inverted polyp の 2 例	日本消化器内視鏡学会誌	54(1)	24-32	2012
Gotoh K, Inoue M, Masaki T, Chiba S, Shimasaki T, Ando H, Fujiwara K, Katsuragi I, Kakuma T, <u>Seike M</u> , Sakata T, Yoshimatsu H.	A novel anti-inflammatory role for spleen-derived interleukin-10 in obesity-induced hypothalamic inflammation.	J Neurochem.	120 (5)	752-64.	2012
Inoue M, Gotoh K, <u>Seike M</u> , Masaki T, Oribe J, Honda K, Kakuma T, Yoshimatsu H.	Involvement of remnant spleen volume on the progression of steatohepatitis in diet-induced obese rats after a splenectomy.	Hepatol Res.	42(2)	203-12.	2012
Nagamatsu H, Takahashi K, Ueo T, Narita R, Mukai T, Ishida T, Fukuzawa K, Wakasugi K, Takagi H, Yonemasu H, <u>Seike M</u> , Koba I.	A case of splenic artery aneurysm simulating a pancreas tumor.	Nihon Shokakibyō Gakkai Zasshi.	108 (8)	1420-7.	2011